LEP Genotype

If you have struggled with severe weight gain since childhood, or if extreme obesity runs in your family, this test asks a question routine labs cannot answer: is your hunger and fullness system wired correctly at the source? Leptin is the hormone your fat cells release to tell your brain you have eaten enough. Variants in the LEP gene can quietly change how much leptin your body makes, or whether it works at all.

The LEP (leptin) gene comes in two flavors of variation. Rare damaging mutations are uncommon but powerful, producing severe, very early obesity and hormone problems. Common polymorphisms in the gene's regulatory regions have smaller, harder-to-pin-down effects on weight, blood sugar, and cardiovascular risk that show up in some populations but not others.

What This Test Looks At

The LEP gene sits on chromosome 7 and contains three exons (only two of which code for protein). The test reads specific positions in this gene to determine which versions you carry. Two alleles, one from each parent, combine to give your genotype.

Across very large databases, potentially damaging LEP variants are rare. Early estimates put heterozygous carriers (people with one altered copy) at roughly 1 in 1,050 people and full homozygous deficiency (two altered copies) at about 1 in 4.4 million. A more recent analysis using a much larger genomic database (gnomAD, with over 140,000 samples) put these figures lower still, at roughly 1 in 2,100 heterozygous carriers and about 1 in 17.8 million for homozygous deficiency. Either way, common regulatory variants like G-2548A (also called rs7799039) and A19G are far more frequent and show up in a meaningful fraction of every population studied.

Severe Early-Onset Obesity

This is the strongest, clearest signal LEP genotyping delivers. Two damaged copies of the LEP gene cause congenital leptin deficiency, with extreme hunger (called hyperphagia) and severe obesity starting in infancy. Frameshift mutations, which scramble the protein's structure, make up about 48% of variants seen in patients with leptin deficiency.

Even one altered copy can matter. In a large French cohort of 1,486 people with severe obesity, 1.7% carried homozygous variants and 6.7% carried heterozygous variants in the leptin pathway (LEP and three related genes: LEPR, POMC, and PCSK1). Adults with two damaged copies had a higher BMI (66 versus 53 kg/m²), an earlier onset of obesity (age 0.4 versus 5.4 years), more impulsive eating, and more frequent hormone abnormalities. Heterozygous carriers sometimes looked clinically similar to homozygotes.

What this means for you: if you have severe obesity that began in early childhood, especially with intense hunger or endocrine issues, identifying a LEP variant changes the conversation. A targeted therapy (recombinant leptin, called metreleptin) has been used successfully in people with two damaged copies, though in the United States its FDA-approved indication is for generalized lipodystrophy; use for congenital leptin deficiency is largely off-label. Standard labs do not flag this; only genetic testing does.

Cardiovascular and Metabolic Risk

For common LEP variants, the cardiovascular story is genuinely mixed and depends on which population you belong to. In a small study of 300 Iranian adults, carrying two copies of the G-2548A variant (the GG or AA genotypes) was linked to about two to four times higher risk of having type 2 diabetes alongside coronary artery disease compared with the more common GA genotype. The GG genotype was also associated with obesity and higher plasma leptin levels. Because this was a single study with a modest sample size, the result needs replication in larger cohorts.

A rare LEP variant called C538T was found in a family-based study of 1,428 individuals to substantially influence pulse pressure and the thickness of the carotid artery wall, an early sign of atherosclerosis. The same rare variant did not affect BMI or circulating leptin in that study, suggesting it acts on blood vessels through a different route.

By contrast, in a multi-ethnic Malaysian study of 408 people, the common A19G and G2548A variants showed no clear effect on blood pressure, body measurements, or leptin levels. Genome-wide work covering roughly 32,000 people identified the LEP region as one of five loci affecting circulating leptin levels, but most effects were independent of BMI and modest in size.

Reconciling the Mixed Findings

It is tempting to read these conflicting results as the test being unreliable. A better framing: common LEP variants are background modifiers, not disease switches. Their effect depends on your ancestry, your sex, your weight, your diet, and other genes you carry. Rare damaging LEP variants behave very differently, with strong, predictable consequences. The same gene can carry both kinds of information, and which kind matters for you depends on which variant you happen to have.

Reproductive Health and Pregnancy

The rs7799039 variant has been studied in pregnancy and fertility. In 147 pregnant women, those carrying the AA genotype stayed at lower body weight but had a higher risk of excessive gestational weight gain. Leptin concentrations during pregnancy were not changed by the variant.

In a study of 468 Iranian women, the GG genotype at the same position was significantly more common in women with polycystic ovary syndrome (PCOS) and infertility than in women without PCOS. This does not mean the variant causes PCOS, but it sits within the metabolic picture of the condition.

Other Conditions Linked to LEP Variants

Smaller studies have associated LEP promoter variants with prostate cancer risk and severity, non-small cell lung cancer susceptibility, colorectal cancer survival (modified by red meat intake and BMI), and antipsychotic-induced weight gain. The prostate cancer signal has held up in some meta-analyses but other associations are population-specific and have not been consistently replicated.

This Result Is For Life

Your LEP genotype is fixed from conception. You do not need to retest the gene itself. The value of this test comes from acting on the result over years, not from running it again. If a variant is identified, the practical question becomes which downstream measurements to track more closely. For carriers of damaging variants linked to severe obesity, that often means leptin levels, fasting insulin, glucose tolerance, lipid panels, and growth or hormone markers in children. For carriers of common variants linked to cardiovascular or metabolic risk, standard prevention metrics (ApoB, blood pressure, HbA1c, hs-CRP) become more important to monitor frequently.

If you have not been tested and you have severe early-onset obesity, hyperphagia from infancy, or a strong family history of extreme obesity, the test is worth pursuing once. The cost of waiting is high because targeted therapies exist for the rare deficiency form, and standard weight-loss approaches often fail in carriers without the right diagnosis.

What an Unexpected Result Should Trigger

If the test flags a damaging or potentially damaging LEP variant, the next steps are predictable. Confirm the variant with a different method if there is any doubt about the call. Order serum leptin to see whether your body is producing the hormone (very low levels suggest deficiency). Get a full metabolic workup including fasting insulin, HOMA-IR, glucose tolerance, and lipids. For children, add growth, pubertal, and pituitary hormone assessments. Refer to an endocrinologist or obesity medicine specialist familiar with monogenic obesity.

For variants of uncertain significance (VUS), do not let the lab report drive treatment alone. Roughly one quarter of clinical genetic results in one large registry had conflicting interpretations across labs, and clinically significant conflicts affected about 5% of patients in one cohort. A genetic counselor can help you weigh whether the variant warrants any change in monitoring, given your family history.

For common polymorphisms (such as rs7799039 GG or AA), treat the result as a modifier of risk rather than a diagnosis. The decision is whether to monitor cardiometabolic markers more frequently and whether your family should be aware, not whether to start any specific treatment.

When Results Can Be Misleading

• Variant panel coverage: this test only detects the variants it was designed to detect. A clean result does not rule out other rare LEP changes that fall outside the panel's scope. If clinical suspicion is high (severe early-onset obesity with very low leptin), full gene sequencing may be warranted.
• Ancestry-specific allele frequencies: many LEP findings come from specific populations (Iranian, Mediterranean, Malaysian, European). The clinical meaning of a variant detected in your sample depends on what is typical in your ancestral background.
• Variants of uncertain significance: an unexpected change in the LEP gene may be reported with unknown clinical meaning. Classifications are revised over time as more data accumulates, so a VUS today may become clearly benign or clearly pathogenic later.
• Clinical-grade versus consumer assay differences: if you have seen a 23andMe-style report mentioning LEP or rs7799039, that is not a substitute for clinical-grade genotyping with confirmation. Direct-to-consumer reports often genotype a single position and do not look across the gene.

Where This Test Fits Among Related Markers

LEP genotyping is one piece of a larger picture for severe obesity and metabolic risk. It is most informative when paired with a measurement of circulating leptin (which shows whether your body is actually making the hormone), and standard metabolic and lipid markers (to assess current cardiometabolic status). For severe early-onset obesity, a fuller leptin-melanocortin pathway panel (covering LEPR, POMC, PCSK1, MC4R, and others) typically uncovers more cases than testing LEP alone. In one cohort of 395 severely obese patients, an expanded 20-gene panel found pathogenic variants in 8.6%.